Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report


Some hereditary ovarian cancer cases can be associated with a mutation of a gene involved in the DNA double-strand break repair system other than BRCA, such as BRIP1. This mutation is an emerging indication for prophylactic risk-reducing salpingo-oophorectomy (RRSO): however, anomalous tubal pathologic lesions have not yet been reported during RRSO performed for this specific indication (BRIP1), as largely reported for BRCA mutation carriers. An asymptomatic 64-year-old woman with a family history of ovarian and breast cancer agreed to undergo RRSO for a pathogenic variant of the BRIP1 gene (heterozygous NM_032043.2: c.124delT, p. Cys42Valfs) with normal BRCA genes. Histological examination showed the presence of high-grade serous carcinoma of the fimbria of the right tube of a maximum diameter of 0.4 cm (final FIGO stage IIB). The pathogenic mechanism that leads to the development of high-grade serous ovarian/fallopian tube cancer in patients with mutations of BRIP1 should be the same as for patients with mutations of BRCA1 and 2. Our case confirms to consider BRIP1 mutation to be sufficient to justify RRSO at 45–50 years old.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Data availability

If requested.


  1. 1.

    Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE (1999) Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 72(3):367–379

    CAS  Article  Google Scholar 

  2. 2.

    Mutch DG, Prat J (2014) 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol 133(3):401–404

    Article  Google Scholar 

  3. 3.

    Antoniou A et al (2003) Average risks of breast cancer and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130

    CAS  Article  Google Scholar 

  4. 4.

    Song H et al (2014) The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet 23(17):4703–4809

    CAS  Article  Google Scholar 

  5. 5.

    Toss A et al (2015) Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 015:341723

    Google Scholar 

  6. 6.

    Rafnar T et al (2011) Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 43(11):1104–1107

    CAS  Article  Google Scholar 

  7. 7.

    Ramus SJ et al (2015) Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 107(11):djv214

    Article  Google Scholar 

  8. 8.

    Weber-Lassalle N et al (2018) BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res 20(1):7

    Article  Google Scholar 

  9. 9.

    Toss A et al (2019) Hereditary ovarian cancers: state of the art. Minerva Med 110(4):301–319

    Article  Google Scholar 

  10. 10.

    National Comprehensive Cancer Network (2020) NCCN Clinical Practice guidelines in oncology. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1. 2020 – December 4, 2019. . Accessed 15 Apr 2020

  11. 11.

    Vang R, Shih IM, Kurman RJ (2013) Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62(1):44–58

    Article  Google Scholar 

  12. 12.

    Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100(1):58–64

    CAS  Article  Google Scholar 

  13. 13.

    Seal S et al (2006) Truncating mutations in the Fanconi anaemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241

    CAS  Article  Google Scholar 

  14. 14.

    Ring KL, Garcia C, Thomas MH, Modesitt SC (2017) Current and future role of genetic screening in gynecologic malignancies. Am J Obstet Gynecol 217(5):512–521

    Article  Google Scholar 

  15. 15.

    Kuchenbaecker KB et al (2017) Risk of breast, ovarian and controlateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416

    CAS  Article  Google Scholar 

Download references


No fundings for this short communication.

Author information




GG: concept, interpretation, manuscript draft, final approval; MC: interpretation, manuscript revise, final approval; CA: study execution, manuscript revise, final approval; LC: interpretation, manuscript revise, final approval; AT: interpretation, manuscript revise, final approval; EB: interpretation, manuscript revise, final approval; LB: study execution, final approval; FF: concept, manuscript revise, interpretation, final approval.

Corresponding author

Correspondence to Giovanni Grandi.

Ethics declarations

Conflict of interest

All authors declares that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Grandi, G., Caroli, M., Alboni, C. et al. Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report. Familial Cancer 19, 291–295 (2020).

Download citation


  • BRIP1
  • Risk-reducing salpingo-oophorectomy
  • Hereditary ovarian cancer
  • Primary carcinoma of the fallopian tube
  • BRCAness
  • Double-strand break repair